SG11201903195YA - Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders - Google Patents
Substituted pyrido[3,4-b]indoles for the treatment of cartilage disordersInfo
- Publication number
- SG11201903195YA SG11201903195YA SG11201903195YA SG11201903195YA SG11201903195YA SG 11201903195Y A SG11201903195Y A SG 11201903195YA SG 11201903195Y A SG11201903195Y A SG 11201903195YA SG 11201903195Y A SG11201903195Y A SG 11201903195YA SG 11201903195Y A SG11201903195Y A SG 11201903195YA
- Authority
- SG
- Singapore
- Prior art keywords
- sanofi
- frankfurt
- main
- international
- aventis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (en) | 2016-11-07 | 2016-11-07 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| PCT/EP2017/078026 WO2018083157A1 (en) | 2016-11-07 | 2017-11-02 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903195YA true SG11201903195YA (en) | 2019-05-30 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903195YA SG11201903195YA (en) | 2016-11-07 | 2017-11-02 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US11130755B2 (es) |
| EP (3) | EP3318563A1 (es) |
| JP (1) | JP7046063B2 (es) |
| KR (1) | KR102490199B1 (es) |
| CN (1) | CN110382496B (es) |
| AR (1) | AR110136A1 (es) |
| AU (2) | AU2017353381B2 (es) |
| BR (1) | BR112019007901A2 (es) |
| CA (1) | CA3042332A1 (es) |
| CL (1) | CL2019001251A1 (es) |
| CO (1) | CO2019005090A2 (es) |
| CR (1) | CR20190217A (es) |
| DK (1) | DK3535263T3 (es) |
| DO (1) | DOP2019000112A (es) |
| EA (1) | EA038365B1 (es) |
| EC (1) | ECSP19031458A (es) |
| ES (1) | ES2837765T3 (es) |
| HR (1) | HRP20201754T1 (es) |
| HU (1) | HUE052187T2 (es) |
| IL (1) | IL265982B (es) |
| LT (1) | LT3535263T (es) |
| MA (1) | MA45803B1 (es) |
| MX (1) | MX2019005308A (es) |
| MY (1) | MY189589A (es) |
| PE (1) | PE20191032A1 (es) |
| PH (1) | PH12019500997A1 (es) |
| PT (1) | PT3535263T (es) |
| RS (1) | RS61172B1 (es) |
| SG (1) | SG11201903195YA (es) |
| SI (1) | SI3535263T1 (es) |
| TN (1) | TN2019000143A1 (es) |
| TW (1) | TWI753966B (es) |
| UY (1) | UY37473A (es) |
| WO (1) | WO2018083157A1 (es) |
| ZA (1) | ZA201902111B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3735419A4 (en) | 2018-01-05 | 2021-09-15 | Icahn School of Medicine at Mount Sinai | PROCESS FOR INCREASING THE PROLIFERATION OF PANCREATIC BETA CELLS, PROCESS OF TREATMENT AND COMPOSITION |
| CA3093340A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| WO2021023813A1 (en) * | 2019-08-06 | 2021-02-11 | Domain Therapeutics | 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| WO2003039545A2 (en) | 2001-11-07 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| WO2006013739A1 (ja) | 2004-08-04 | 2006-02-09 | Konica Minolta Holdings, Inc. | 有機エレクトロルミネッセンス素子、照明装置及び表示装置 |
| AU2007287510B2 (en) | 2006-08-25 | 2012-08-30 | Ares Trading S.A. | Treatment of cartilage disorders with FGF-18 |
| WO2008132454A1 (en) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| WO2010038153A1 (en) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Use of sox transcription factor acti\ators for stimulating chondrogenesis |
| EP2455378A1 (en) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/en not_active Withdrawn
-
2017
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/en active Active
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/en unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 MX MX2019005308A patent/MX2019005308A/es unknown
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/en active Pending
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 BR BR112019007901A patent/BR112019007901A2/pt unknown
- 2017-11-02 CA CA3042332A patent/CA3042332A1/en active Pending
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active IP Right Grant
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es unknown
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-06 PH PH12019500997A patent/PH12019500997A1/en unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2020
- 2020-10-30 HR HRP20201754TT patent/HRP20201754T1/hr unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US20240182469A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903195YA (en) | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | |
| SG11201906209SA (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| SG11201909924VA (en) | Rapamycin analogs as mtor inhibitors | |
| SG11202000325UA (en) | Selective inhibitors of nlrp3 inflammasome | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407860PA (en) | Exendin-4 peptide analogues | |
| SG11201804577RA (en) | Fgf21 variants | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201408123SA (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201909243TA (en) | New bicyclic pyrazole derivatives | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea |